Medical Tidbits,Young Woman with Juvenile Arthritis and Dysautonomia Sees Major Improvements after Receiving Her Own Adult Stem Cells

pharmaceuticals

falling-pill-capsules-5_zyvrwhlbb__S0000

HOUSTON–(EON: Enhanced Online News)–A 23-year-old woman with systemic juvenile idiopathic arthritis (SJIA) and another related disorder called dysautonomia is seeing major improvements in her quality of life after receiving her own adult mesenchymal stem cells (MSCs), thanks to Houston-based biotechnology company Celltex Therapeutics Corporation. read more

Illumina Joins WIN Consortium in Personalized Cancer Medicine

SAN DIEGO & VILLEJUIF, France–(EON: Enhanced Online News)–Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, today announced it has joined the Worldwide Innovative Networking (WIN) Consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, insurance and non-profit research organizations working to make personalized cancer care a reality for patients worldwide. read more

Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative Pain

REDWOOD CITY, Calif.–(EON: Enhanced Online News)–Heron Therapeutics, Inc. (NASDAQ: HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced positive, top-line results from its Phase 2 clinical study of HTX-011 in the management of post-operative pain in patients undergoing bunionectomy. HTX-011, which utilizes Heron’s proprietary Biochronomer® drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. The primary and all key secondary endpoints in the study were met with a high degree of statistical significance. read more

IDT Biologika Launches U.S. Manufacturing Operations with Opening of Rockville Facility for Vaccine Development Manufacturing

ROCKVILLE, Md.–(BUSINESS WIRE)–IDT Biologika announces today the dedication of its first U.S. vaccine manufacturing facility in Rockville, Maryland. The state-of-the-art facility provides the translational bridge between pre-clinical development and phase II clinical trials with end-to-end capabilities, including process development, cell banking, cGMP manufacturing, purification and formulation, and fill and finish. read more

New FDA Approved Treatment for Colon Cancer

FDA approved trifluridine/tipiracil (LONSURF, Taiho Oncology, Inc.) for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- , and irinotecan-based chemotherapy, an anti-VEGF biologic product, and an anti-EGFR monoclonal antibody, if RAS wild-type. September 22, 2015.  More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm463743.htm

New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression

 

Subscribe today for leading medical news and career advice from top  medical recruiters!

Subscribe today for leading medical news and career advice from top medical recruiters!

 

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.